Clinically relevant differences in survival according to histology
2nd-line retrospective analysis: Overall survival (OS) of ALIMTA vs docetaxel in advanced NSCLC by histologic subgroups1,2
Based on a retrospective analysis, ALIMTA was less effective than docetaxel in patients with advanced squamous NSCLC.
Limitation of Use: ALIMTA is not indicated for the treatment of patients with squamous cell non-small cell lung cancer.
CI=confidence interval.View Trial Design
OS of ALIMTA compared with docetaxel in 2nd-line advanced NSCLC (ITT population) (N=571)1,2
This study did not show an improvement in OS in the ITT population.
The data presented here did not imply noninferiority between ALIMTA and docetaxel.
Data included patients with advanced squamous NSCLC. In subgroup analyses, there was no evidence of a treatment effect on survival in patients with squamous NSCLC.
Secondary endpoint: Median progression-free survival† (ITT population) (months) (95% CI)
ALIMTA (n=283): 2.9 (2.4-3.1); Docetaxel (n=288): 2.9 (2.7-3.4); HRa (95% CI): 0.97 (0.82-1.16)
Secondary endpoint: Overall response rate† (ITT population) (95% CI)
ALIMTA (n=283): 8.5% (5.2-11.7); Docetaxel (n=288): 8.3% (5.1-11.5)